丰原药业(000153) - 2025 Q3 - 季度财报

Revenue and Profit - Revenue for Q3 2025 reached ¥1,098,001,872.02, an increase of 15.15% compared to the same period last year[4] - Net profit attributable to shareholders decreased by 49.02% to ¥24,005,835.11 for Q3 2025, and by 31.92% to ¥100,284,311.64 year-to-date[4] - The net profit excluding non-recurring gains and losses fell by 55.22% to ¥14,388,898.42 in Q3 2025, and by 36.39% to ¥74,915,110.67 year-to-date[4] - Net profit for the current period was ¥98,215,098.62, a decline of 32.3% compared to ¥145,091,092.54 in the previous period[15] - The company reported a total profit of ¥113,949,975.44, down from ¥185,882,970.71, a decrease of 38.7%[15] Assets and Liabilities - Total assets increased by 5.73% to ¥4,968,400,794.45 compared to the end of the previous year[4] - The company's total current assets amount to ¥2,091,934,911.00, an increase from ¥1,965,350,782.21 at the beginning of the period[11] - Total non-current assets are reported at ¥2,876,465,883.45, up from ¥2,733,596,633.00, indicating an increase of approximately 5.2%[12] - Total liabilities increased to ¥2,842,428,116.17, up from ¥2,653,036,981.33, marking a growth of 7.13%[13] - Total equity rose to ¥2,125,972,678.28, compared to ¥2,045,910,433.88, an increase of 3.93%[13] Cash Flow - Cash flow from operating activities for the year-to-date was ¥88,813,551.80, up 29.73%[4] - Cash flow from operating activities was ¥2,477,831,768.62, down from ¥2,682,758,366.83, a decrease of 7.63%[16] - Net cash flow from operating activities was $88,813,551.80, an increase from $68,460,340.27 in the previous period, reflecting a growth of approximately 29.5%[17] - Total cash inflow from investment activities was $10,008,385.25, down from $35,392,875.10, indicating a decline of about 71.7%[17] - Net cash flow from financing activities increased to $85,791,438.85, compared to $32,337,711.28 in the prior period, representing a growth of approximately 165.5%[18] Shareholder Information - The total number of common shareholders at the end of the reporting period is 39,078[8] - The largest shareholder, Anhui Wuwei Pharmaceutical Factory, holds 10.80% of shares, totaling 50,178,992 shares[8] Expenses and Costs - Sales expenses decreased by 33.08% to ¥257,448,980.46, reflecting reduced market expansion costs[7] - Total operating costs decreased to ¥3,040,766,325.73, down 2.31% from ¥3,112,687,590.78[14] - Income tax expenses decreased by 61.43% to ¥15,734,876.82, primarily due to a reduction in total profit compared to the previous year[7] Investments and Financial Activities - The company reported a significant increase in construction in progress by 33.87% to ¥595,887,726.60, attributed to increased project investments[7] - Long-term borrowings rose by 39.62% to ¥273,834,238.47, indicating new long-term financing[7] - Short-term borrowings increased to ¥493,312,430.59 from ¥479,333,465.88, reflecting a rise of approximately 2.1%[12] - Accounts payable rose significantly to ¥626,718,216.45 from ¥393,220,072.10, an increase of about 59.5%[12] Other Financial Metrics - Earnings per share (EPS) decreased to ¥0.2158 from ¥0.3169, reflecting a 31.8% drop[15] - Other comprehensive income after tax for the current period was ¥24,669,992.92, compared to a loss of ¥808,596.84 in the previous period[15] - The company recorded a 114.83% increase in fair value gains to ¥1,470,294.35, driven by changes in non-current financial assets[7]